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Esa Leinonen2,3 and Terho Lehtimäki2,8Abstract
Background: In major depression, one of the candidate genes possibly affecting the risk and severity of symptoms
has been found to be tryptophan hydroxylase (TPH1). Variation in treatment response to antidepressive agents
according to TPH1 genotype has also been found in several studies. However, the relationship between
temperament and TPH1 genotype in major depression is poorly understood, as only one study has been published
so far. There are no earlier studies on the interaction between temperament traits, antidepressive medication
response and TPH1 genotype. This interaction was studied in 97 subjects with major depression treated for six
weeks with selective serotonine reuptake inhibitors.
Methods: Temperament dimensions Harm Avoidance (HA), Novelty Seeking (NS), Reward Dependence (RD) and
Persistence (P) scores at baseline (1) and endpoint (2) were rated with the Temperament and Character Inventory
(TCI) and compared between TPH1 A218C genotypes. Multivariate analysis of co-variance (MANCOVA) was used to
analyze the interaction between the TPH1 genotype, treatment response and the different temperament
dimensions at baseline and endpoint. In the analysis model, treatment response was used as a covariate and TPH1
genotype as a factor. A post hoc analysis for an interaction between remission status and TPH1 A218C genotype at
endpoint HA level was also performed.
Results: The number of TPH1 A-alleles was associated with increasing levels in NS1 and NS2 scores and decreasing
levels in HA1 and HA2 scores between TPH1 A218C genotypes. In the MANCOVA model, TPH1 genotype and
treatment response had an interactive effect on both HA1 and HA2 scores, and to a lesser degree on NS2 scores.
Additionally, an interaction between remission status and TPH1 A218C genotype was found to be associated with
endpoint HA score, with a more marked effect of the interaction between CC genotype and remission status
compared to A-allele carriers.
Conclusions: Our results suggest that in acute depression TPH1 A218C polymorphism and specifically the CC
genotype together with the information on remission or treatment response differentiates between different
temperament profiles and their changes.
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Tryptophan hydroxylase (TPH) is a rate-limiting enzyme
involved in the synthesis of neurotransmitter serotonin
(5-HT) and therefore determines the levels of 5-HT be-
ing released [1]. TPH1 A218C polymorphism has been
suggested to have an impact on depressive disorders and
suicidal behavior [2]. According to a meta-analysis the
overall response rate to antidepressive treatment was
found to be better for CC-genotype than for A-allele
carriers. However, only two of the studies included
showed a significantly better response for A-carriers [3].
By contrast, in a study where TPH1 CC-genotype was
found to occur more commonly among patients with
major depression, the same genotype was associated
both with the severity of the disease and with lower
probability of achieving remission [4].
So far only one study has been published on tempera-
ment traits and TPH1 A218C polymorphism in major
depression; it reports a negative result between HA or
NS scores and TPH1 genotypes [5]. The C allele of
A218C has been reported to be more common among
nonorganic and nonpsychotic inpatients with impulsive
behavioral traits [6]. Higher harm avoidance scores and
more severe binge eating behavior were observed among
bulimic women with AA genotype [7]. High scores on
HA were found with AA genotype of TPH1 and a hostile
childhood environment in a study on healthy adults
exploring the role of earlier socioeconomic factors [8].
In a sample of healthy Chinese subjects a trend towards
higher novelty seeking scores was found among men
with CC genotype [9].
The TPH enzyme occurs in two different isoforms
[10]. TPH1 gene is located on chromosome 11p15.3-p14
and is expressed in the gut, spleen, thymus, but also in
the pineal gland and in the pituary [11] TPH1 gene
variants may have an influence on the level of serotonin
metabolites and their functionality, because lower cere-
brospinal fluid 5-hydroxyindoleacetic acid (5-HIAA)
levels were found in men with the TPH1 A218C A-
allele, but not in women [12]. However, another study
on the association of A218C with serotonin metabolites
resulted in negative findings [13]. TPH1 A218C poly-
morphism has been observed to have an effect on amyg-
dala activity; subjects with the A allele showed greater
brain activity in the bilateral amygdala under sad vs.
neutral condition than subjects homozygous for the
C allele [14].
The TCI is a questionnaire which distinguishes four
temperament dimensions, namely Harm Avoidance
(HA), Novelty Seeking (NS), Reward Dependence (RD)
and Persistence (P) [15]. Several studies, including our
earlier study [16], report negative outcomes concerning
the association between TPH1 genotype, depression and
its treatment response [5,17]. In a number of studiestemperament traits, and most importantly HA, have
shown an impact on recovery from depression [18].
We investigated the interaction between TPH1 A218C
polymorphism, SSRI treatment response and tempera-
mental traits assessed by the Temperament and Charac-
ter Inventory (TCI) in a clinical sample of subjects with
major depression. The primary aim of the study was to
analyze the relationship between temperament dimensions
and TPH1 genotype, with treatment response as a second-
ary aim. The study hypotheses included 1) relationship be-
tween TPH1 genotype and temperament dimensions and
2) interactive effect of TPH1 genotype and antidepressive
response on temperament dimensions.
Methods
Study subjects and clinical intervention
The patients were recruited for a pharmacogenetic study
on depression during the time period from September
2002 to December 2006. The population consisted of 97
individuals 19-72 years of age (41 males and 56 females,
age mean [SD] 40.5 [14.1] years). All subjects were pa-
tients in secondary outpatient services in Pirkanmaa
Hospital District, Finland (total catchment population ap-
proximately 300,000). Study inclusion criteria were: 1)
current episode of major depressive disorder according to
DSM-IV criteria and 2) a Montgomery Åsberg Depression
Rating Scale (MADRS) [19] score of at least 20. Treatment
response was taken to be a reduction of at least 50%
in MADRS score during follow-up, and remission as
MADRS scores of 7 or less. The dosage of the study medi-
cation was adjusted according to the clinical response,
which was checked after three weeks during a short study
visit. Medication adherence was self-monitored by keeping
a paper-and-pencil medication diary. At least 80% adher-
ence rate was considered adequate treatment.
The clinical researchers interviewed each patient be-
fore the initial assessment for the study. Patients with
major somatic diseases and those with medications
potentially causing depression were excluded, likewise
patients with bipolar disorder, schizophrenia, severe
personality disorders or disorders related to substance
abuse. Patients had to have been free of antidepressive
medications for the past three months, and mood stabil-
izing or anti-psychotic medications were not allowed.
Anxiolytics and hypnotics in minor doses were permit-
ted at the early stage of the study.
Patients completed the 107-item TCI temperament
questionnaire (version IX) at the initial assessment of
the study and after six weeks of follow-up. All subjects
received SSRI medication, citalopram, fluoxetine or par-
oxetine (the three most frequently prescribed SSRIs in
Finland at the time of the study). All patients gave writ-
ten informed consent and the local ethics committee
approved the study protocol.
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Genomic DNA was extracted from peripheral blood
leukocytes using QIAampWDNA Blood Minikit and
automated biorobot M48 extraction (Qiagen, Hilden,
Germany). TPH1 A779C (rs1799913) was genotyped with
TaqmanWSNP Genotyping Assay C_2645661_10 and
TPH1 A218C (rs 1800532) with a custom Taqman Assay
(Applied Biosystems). Information on oligos and PCR
protocol are available from the corresponding author.
TPH1 A218C and A779C polymorphisms were in
complete linkage disequilibrium in the present study
subjects. Thus, to avoid repetition, only the results
concerning A218C polymorphisms are reported here.
Statistical methods
Temperament dimension HA, NS, RD and P scores at
baseline (1) and endpoint (2) during antidepressive treat-
ment were analyzed between TPH1 genotypes with
ANOVA including Bonferroni correction. Before the
ANOVA analyses, the normality of distributions was
checked in each temperament/genotype subgroup, and
these showed normal distributions. Multivariate analysis
of co-variance (MANCOVA) was used to explain the dif-
ferent temperament dimensions (HA, NS, RD and P) at
baseline and endpoint. In the model, treatment response
was used as a covariate and TPH1 genotype as a factor.
Finally, as a post-hoc analysis, the HA endpoint scoreFigure 1 Mean harm avoidance endpoint scores in remitters and non
The interaction of TPH1-genotype (CC vs. CA/AA) and the remission status
power = 0.98, GLM univariate model).was predicted by the interaction of TPH1 A-allele carry-
ing and remission status with a GLM univariate model
(Figure 1).
In power analysis the temperament score limits were
determined in such a way that we were able to detect
with a statistical power of ≥0.8 between different TPH1
genotype groups. They were 3.4, 3.9 and 4.4 between
CC/CA (n = 73), CC/AA (n = 56), and CA/AA (n = 45)
respectively.
Results
Frequencies of baseline and endpoint medications, dis-
tributions of corresponding temperament traits, and
depressive symptoms are given in Table 1. In keeping
with the primary aim of the study in comparisons with
TCI temperament dimensions and TPH1 genotypes, we
observed a linearly increasing change between TPH1 CC
(n = 34/31), CA (n = 47/42) and AA (n = 16/14) geno-
types in NS1 and NS2 scores (NS1: CC 17.2 ± 7.4, CA
19.8 ± 7.1, AA 23.6 ± 7.2, p = 0.016; NS2: CC 18.7 ± 6.7,
CA 20.6 ± 7.7, AA 26.4 ± 5.7, p = 0.005). A similar, but
decreasing change was found in HA1 between TPH1
genotypes and to a lesser degree in HA2 (HA1: CC 25.4 ±
6.6, CA 23.8 ± 6.5, AA 19.8 ± 7.6, p = 0.027; HA2: CC
23.2 ± 8.5, CA 22.3 ± 7.5, AA 17.2 ± 6.9, p = 0.055). In
P1, a trend level difference was found between TPH1
genotypes (CC 4.0 ± 2.2, CA 4.9 ± 2.0, AA 3.7 ± 1.6,-remitters according to TPH1 A-allele carrying status.
significantly explained the HA endpoint score (p < 0.001, ηp2 = 0.209,
Table 1 Frequencies of medications and distributions of temperament traits and depressive symptoms during the
study
Variable Baseline (n = 97) Endpoint (6 weeks, n = 87)
Antidepressive medication N % N %
Citalopram 50 51.5 44 50.6
Paroxetine 12 12.4 11 12.6
Fluoxetine 35 36.1 32 36.8
Use of hypnotics 32 33.0
Use of anxiolytics 22 22.7
Temperament scores mean SD mean* SD
NS 19.5 7.5 20.8 7.4
HA 23.7 6.9 21.8 7.9
RD 15.5 3.9 15.9 3.7
P 4.3 2.0 4.3 2.0
MADRS score 26.9 5.6 12.2 8.2
Antidepressant dose, mg 19.8 2.7 22.3 6.5
*n = 86.
NS novelty seeking, HA harm avoidance, RD reward dependence, P persistence.
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in temperament scores between genotypes were found.
In keeping with the secondary aim of the study a
MANCOVA analysis was performed. The results of the
MANCOVA model are presented in Table 2. The GLM
univariate model with HA2 as a target variable and
TPH1 A allele carrying and remission status as explana-
tory variables showed an interactive effect (p < 0.001,
ηp2 = 0.209, power = 0.98; Figure 1). In this model, the
CC genotype when compared to A-carriers had a more
marked interactive effect with remission status on the
post-treatment HA level.
Discussion
This is the first study to investigate the interaction
between temperament traits, antidepressant treatment
response and TPH1 A218C genotype. AssociationsTable 2 Results of the MANCOVA model, in which all tempera
at endpoint (2) were used as target variables and TPH1 geno
Complete model
Target variable ηp2 p Power
HA1 0.186* 0.001 0.96
HA2 0.252 <0.001 1.00
NS1 0.139 <0.001 0.86
NS2 0.199 <0.001 0.97
RD1 0.071 0.11 0.51
RD2 0.042 0.32 0.31
P1 0.082 0.07 0.59
P2 0.112 0.02 0.76
* ηp2 = explanatory proportion of the complete model for the target variable.
** ηp2 = explanatory proportion of the single factor or covariate for the target variabetween TPH1 genotype and temperament dimensions
were studied in patients with major depressive disorder
and linear changes were found at both baseline and end-
point. Subjects with the C-allele of A218C scored higher
on HA and lower on NS. HA scores were higher at base-
line than at endpoint and NS scores increased from
baseline to endpoint. In multivariate analysis of covari-
ance (MANCOVA) TPH1 genotype was used as a factor
and MADRS scores as a covariate, since depressive
symptoms have been found to modify temperamental
traits and, on the other hand, temperament has an
impact on recovery from depression [18]. HA and NS
scores at baseline were analyzed as temperament profile
itself can reflect the biological subtype of depression and
be associated with the clinical response. Treatment re-
sponse has been found to affect HA and NS scores at
endpoint [20]. A possible interaction of TPH1 genotypement dimensions (HA, NS, RD and P) at baseline (1) and
type as a factor and MADRS score change as a covariate
TPH1 genotype ΔMADRS
ηp2 p ηp2 p
0.120** 0.005 0.078 0.01
0.079 0.034 0.196 <0.001
0.120 0.005 0.02 0.20
0.127 0.004 0.087 0.006
0.33 0.027 0.091 0.005
ble.
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lyzed in treatment response due to the obvious associa-
tions detected between HA and NS dimensions and
TPH1 genotypes. Additionally, an interaction of remis-
sion status and most markedly with TPH1 CC genotype
was found to be associated with endpoint HA score.
According to this analysis, the endpoint HA score
variation was greater with the CC genotype than with
the AG/AA genotypes when the remission and non-
remission groups were compared. This finding may indi-
cate the CC genotype being associated more with traits
related to risk of depression, including the tendency to
harm avoidance, than with the depressive state itself.
Earlier studies, including one meta-analysis, have
reported contradictory results on the relationship be-
tween TPH1 genotype and treatment response in major
depression [2,4]. In a population based study no associ-
ation was found between TPH1 genotype and TCI tem-
perament dimensions [21]. Both the depressive disorder
among our patients and the different ethnic background
may explain the discrepancy in the results. It was there-
fore important to study the possible interactive effect of
genotype and treatment response on temperament di-
mensions. As the impact of genotype alone is likely very
small it can be hypothesized to be connected with the
depressive trait rather than the clinical state.
According to present results TPH1 genotype and
MADRS scores explained 14-25 percent of the changes
in HA and NS scores from baseline to endpoint. TPH1
genotype explained about half of the variance within the
linear model. HA scores at baseline were explained
mostly by TPH1 genotype (number of A alleles related
with lower HA), and treatment response (better re-
sponse related with lower HA) had less impact. HA
scores at endpoint were explained to a greater extent by
treatment response and less by genotype. The prospect-
ive setting could be considered as a strength of this
study. At follow-up visits the adequacy of antidepressive
treatment was monitored by adherence diaries, symptom
evaluations and dosage adjustments, if necessary. The
limitations of the study are the relatively small patient
sample, in spite of a satisfactory statistical power in sep-
arate analysis. Also, the study setting was focused pri-
marily on the acute treatment response. No structured
interviews were conducted, and thus no evaluation of
axis II disorders was available. It is possible that in some
patients personality disorders had an impact on treat-
ment response.
These results suggest that C allele of TPH1 is associ-
ated with differences in temperament profile. High HA
among C allele carriers may lead to general avoidance
behavior and susceptibility to depression. There is one
earlier study reporting no association between tempera-
ment dimensions and TPH1 genotype [5], but in thissample most of the patients had a diagnosis of bipolar
disorder. The different findings likely reflect the different
genetic backgrounds of bipolar and unipolar depressive
disorders.
Conclusion
According to the present study, TPH1 A218C genotype
differentiates between temperament profiles and changes
therein in acute major depression, which is supported by
genotype-specific differences found in HA and NS
scores at baseline and endpoint during antidepressive
treatment. In the comparison of remitters and non-
remitters, CC genotype had the most marked interactive
effect on HA endpoint scores. Given the clinical state of
major depression and the underlying risk traits, it seems
that despite the achievement of remission the impact of
depression risk traits differs depending on the TPH1
genotype.
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